Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV

Amedeo Lonardo, Stefano Ballestri, Giovanni Guaraldi, Fabio Nascimbeni, Dante Romagnoli, Stefano Zona, Giovanni Targher

Abstract
Fatty liver, which frequently coexists with necro-inflammatory and fibrotic changes, may occur in the setting of nonalcoholic fatty liver disease (NAFLD) and chronic infections due to either hepatitis C virus (HCV) or human immunodeficiency virus (HIV). These three pathologic conditions are associated with an increased prevalence and incidence of cardiovascular disease (CVD) and type 2 diabetes (T2D). In this multidisciplinary clinical review, we aim to discuss the ever-expanding wealth of clinical and epidemiological evidence supporting a key role of fatty liver in the development of T2D and CVD in patients with NAFLD and in those with HCV or HIV infections. For each of these three common diseases, the epidemiological features, pathophysiological mechanisms and clinical implications of the presence of fatty liver in predicting the risk of incident T2D and CVD are examined in depth. Collectively, the data discussed in this updated review, which follows an innovative comparative approach, further reinforce the conclusion that the presence of fatty/inflamed/fibrotic liver might be a shared important determinant for the development of T2D and CVD in patients with NAFLD, HCV or HIV.
review may also open new avenues in the clinical and research arenas and paves the way for the planning of future, well-designed prospective and intervention studies.

Key words: Atherosclerosis; Cardiovascular risk; Fatty liver; Fibrosis; Hepatitis C-associated dysmetabolic syndrome; Hepatitis C virus; Human immunodeficiency virus; Nonalcoholic fatty liver disease; Steatohepatitis; Steatosis; Virus-associated fatty liver disease

© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Normally, the liver is almost devoid of fat and fatty changes often coexist with necro-inflammatory and fibrotic changes in the setting of nonalcoholic fatty liver disease (NAFLD), chronic infection due to hepatitis C virus (HCV) or human immunodeficiency virus (HIV), which have all been associated with an increased prevalence and incidence of cardiovascular disease (CVD) and type 2 diabetes (T2D). On these grounds, in this multidisciplinary clinical review, we discuss the ever-expanding wealth of evidence supporting a key role of fatty liver in the development of T2D and CVD both in patients with NAFLD and in those with HCV or HIV infections.

Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol 2016; 22(44): 9674-9693 Available from: URL: http://www.wjgnet.com/1007-9327/full/v22/i44/9674.htm DOI: http://dx.doi.org/10.3748/wjg.v22.i44.9674

INTRODUCTION
The storage of excess lipids is not among the physiologic functions of the liver, which normally is almost devoid of fat content. Fatty liver is defined as the presence of triglycerides in more than 5% of the hepatocytes. In many cases, such fatty changes (simple steatosis) may frequently coexist with lipotoxic features, such as necro-inflammation and fibrosis (i.e., steatohepatitis), the extent of which depends on the etiology of such liver changes.

Fatty liver may occur in the setting of both metabolic and viral injuries. For example, nonalcoholic fatty liver disease (NAFLD) is defined by fatty changes which occur in individuals without excessive alcohol consumption and who have (or will develop) features of the metabolic syndrome (MetS). Chronic hepatitis C virus (HCV) infection is also commonly associated with fatty liver, which occurs to a variable extent according to the viral genotype and host’s metabolic features. Similarly, human immunodeficiency virus (HIV) infection exhibits fatty liver as a result of multiple viral and host factors, probably including the anti-viral drugs used. Fatty liver associated with these two highly prevalent viral infections has collectively been named “virus-associated fatty liver disease” (VAFLD).

Recent studies have addressed the systemic and cardio-metabolic risks associated with fatty liver due to different etiologies. For example, both NAFLD and VAFLD have been linked with an increased risk of cardiovascular disease (CVD) and type 2 diabetes (T2D). However, in clinical practice, different medical expertise is involved in the diagnosis and management of CVD risk; NAFLD; and HIV mono or co-infection.

In this updated clinical review, we summarize the rapidly expanding body of evidence supporting a contribution of fatty liver per se in the development of CVD and T2D not only in patients with NAFLD but also in those with chronic HCV or HIV infections. For each of these diseases, we extensively discuss the epidemiological burden, pathophysiologic mechanisms and clinical implications of the presence of fatty liver in predicting the risk of developing T2D and CVD. We believe that this review, which follows an innovative multidisciplinary and comparative approach, further reinforces the notion that the fatty/inflamed/fibrotic liver may represent a shared and important determinant for the development of T2D and CVD in patients with any of these three common steatogenic diseases.

NAFLD
Epidemiology, risk factors and natural history of NAFLD
The prevalence of NAFLD in the general adult population is approximately 25%-30% in Europe and United States based on imaging studies, i.e., roughly two-fold higher than that identified through serum liver levels; the highest prevalence of disease is observed in Southern American and Middle Eastern countries while the lowest prevalence is found in Africa. An “inverted U” shaped curve describes the prevalence of NAFLD as a function of increasing age, suggesting that younger and older individuals are relatively more spared from NAFLD.

The incidence rates of NAFLD have been estimated between 52/1000 person-years in Asia and 28/1000 person-years in Israel, respectively. However, very little is known about the incidence rates of NAFLD in Western countries. A pioneering study conducted in northern Italy found that NAFLD incidence was approximately 2/1000 person-years in a sample of women subjected to hysterectomy.

The metabolic predictors of NAFLD are likely to vary based on sex. Compared to women, men are at higher risk of developing NAFLD in most published studies, and post-menopausal women are no longer spared from NAFLD and its fibrotic evolution, owing to ovarian senescence and estrogen deficiency.
It is known that abdominal obesity/overweight, T2D and other MetS features are strongly associated with an increased risk of NAFLD. However, the hierarchy of individual MetS features associated with NAFLD risk varies across the different studies. For example, one can report the prevalence of NAFLD in patients with MetS features as opposed to the prevalence of MetS features in patients with NAFLD (Table 1)[8,15]. Of concern, most of the MetS features listed in Table 1 are positively associated with the development and progression of NAFLD[3,16-19].

The natural history of NAFLD features both hepatic and extra-hepatic outcomes, which have been discussed in detail elsewhere[20-22]. The extra-hepatic outcomes of NAFLD include T2D/metabolic, CVD and cancer. Simple steatosis, with/without minor degrees of necro-inflammatory changes, is the first step in the histogenesis and natural history of NAFLD. Traditionally, NASH has been postulated to develop in a subset of “bad storers”, leading to the notion that simple steatosis and NASH are two different pathologic conditions with little, if any, mutual interconnections[23,24]. However, recent studies have demonstrated that simple steatosis can progress to NASH and that both conditions progress to advanced fibrosis, though this occurs at a much slower pace for simple steatosis than for NASH[16,25-27]. The severity of hepatic fibrosis, rather than NASH, largely dictates the prognosis of liver-related outcomes in NAFLD[21,28,29].

The often used statement “NAFLD is the hepatic manifestation of the MetS” fails to render the mutual and bidirectional link existing between these two diseases. Notably, such statement also fails to pinpoint that NAFLD is a precursor and almost doubles the risk of developing T2D and MetS over a median follow-up period of 5 years[4,20].

Strong evidence also indicates that NAFLD is associated with an increased risk of subclinical atherosclerosis[31-34]. The entity of this NAFLD-related proatherogenic risk is probably linked to the severity of hepatic fibrosis[35], the degree of fatty liver[36], or both. More importantly, follow-up studies have consistently shown that CVD is the leading cause of mortality in NAFLD patients[37,38]. However, it should also be pointed out that fatal and non-fatal CVD complications are not the only dreadful outcomes in patients with NAFLD. Indeed a variety of other cardiac complications have recently been reported in these patients, including aortic-valve stenosis, cardiac arrhythmias, and increased re-hospitalization rates following discharge for acute heart failure[39-41].

Patients with NAFLD have an increased risk of developing hepatic and extra-hepatic cancers. The risk of hepatocellular carcinoma (HCC) is not only confined to patients with cirrhosis and accordingly, in NAFLD patients, HCC tends to escape those surveillance protocols which are a standard of good clinical practice in individuals with viral chronic liver diseases[42-45]. Further to HCC, increased rates of cholangiocarcinoma have been reported in NAFLD patients[46-48]. Finally, a variety of extra-hepatic cancers have also been reported in patients with NAFLD, including colo-rectal, pancreatic and uterine cancers[49], though the consistency of these associations remains to be definitely proven.

**Epidemiological evidence for an association of NAFLD with T2D**

The prevalence of NAFLD is remarkably increased in patients with T2D, ranging from 30% to 75% according to age, ethnicity, the study population and the diagnostic tools used[45].

Several retrospective and prospective studies have shown that NAFLD, as diagnosed either by raised serum liver enzymes or ultrasonography, independently predicts the development of incident T2D and MetS[30,50-52]. Recently, two meta-analyses concluded that NAFLD is associated with a two-fold increased risk of incident T2D and MetS[4,53]. Consistently, an improvement[52,54] or a transient remission of NAFLD significantly decrease risk of new-onset T2D[55].

To date, the only small retrospective cohort study investigating the association between biopsy-proven NAFLD and risk of incident T2D found that most of these NAFLD patients developed T2D over a 13.7-year follow-up, and that T2D risk was almost three-fold higher in patients with NASH than in those with simple...
The presence of T2D also worsens the histological course of NAFLD. Patients with NAFLD and T2D have a high prevalence of NASH and advanced fibrosis, and consistently, T2D is a strong predictor of the severity and progression of histologically assessed hepatic fibrosis. Moreover, T2D is also an important predictor of the development of HCC and an increased risk of all-cause and liver-related mortality. Worryingly, T2D patients often exhibit advanced histological disease with normal serum transaminases and may also develop HCC even in the absence of cirrhosis, resulting in restricted therapeutic options and decreased survival.

**Epidemiological evidence for an association of NAFLD with CVD**

A large number of studies have consistently shown that NAFLD is strongly associated with various markers of subclinical atherosclerosis, independent of traditional CVD risk factors and MetS features. Epidemiological studies have also shown that NAFLD is independently associated with a greater severity of coronary stenoses and an increased prevalence of carotid atherosclerotic plaques. Against this background, a consistent body of evidence also suggests an association between NAFLD and increased incidence of fatal and non-fatal CVD events in NAFLD patients with/without T2D. Indeed, as extensively reviewed elsewhere, population-based cohort studies, have reported a strong and independent association between NAFLD and increased risk of fatal and non-fatal CVD events independent of multiple cardio-metabolic risk factors. Only one of these studies had assessed coronary artery disease (CAD) as a pre-specified outcome; it reported that patients with NAFLD had a higher 10-year risk for CAD as calculated by the Framingham risk score (FRS) than the matched control population, featuring almost the same number of FRS-predicted and actual new CAD events. A recent prospective study, involving 125 patients with ultrasound-diagnosed NAFLD and 250 age- and sex-matched control individuals, followed-up for 10 years, confirmed that the incidence of CVD outcomes was significantly higher in patients with NAFLD. Studies have also highlighted that middle-aged individuals with NAFLD are particularly prone to increased CVD mortality. For example, a study enrolling 980 subjects with NAFLD (diagnosed by elevated serum aminotransferase levels) compared to 6594 NAFLD-free individuals, followed up for 8.7 years, reported that the presence of NAFLD was associated with a higher risk of all-cause and CVD mortality, independently of traditional CVD risk factors in the 45-54 age group. A recent Asian cohort study performed on NAFLD patients submitted to coronary angiography paradoxically showed a reduced CVD incidence over the follow-up period; however, the successful coronary re-vascularization procedures and the intensive lipid-lowering therapy might have dramatically improved the prognosis in this specific cohort of patients.

Notably, several cohort studies with a reasonably long follow-up that used biopsy-proven NAFLD have clearly shown that this disease is associated with an increased risk of all-cause and cause-specific mortality (mainly CVD, cancer-related and liver-related). Most of these studies showed that the severity of hepatic fibrosis was the main determinant of all-cause and cause-specific mortality, and that CVD was the leading cause of death in patients with NAFLD. Despite some studies reporting NASH more closely associated with CVD risk than simple steatosis, a milestone meta-analysis did not find any significant difference in CVD risk among patients with NASH and those with simple steatosis; nevertheless it confirmed an increased CVD risk in patients with NAFLD. Recently, a systematic review and meta-analysis involving 16 observational prospective and retrospective studies with 34043 adult individuals (36.3% with NAFLD) and approximately 2600 CVD outcomes (> 70% CVD deaths) over a median period of 6.9 years found that NAFLD patients had a higher risk of fatal and non-fatal CVD events than NAFLD-free controls. Patients with more “severe” NAFLD were also more likely to develop fatal and non-fatal CVD events.

Of relevance, persistent NAFLD on ultrasound also appears to be a risk factor for incident subclinical atherosclerosis, and by treating NAFLD, we may improve vascular health. In fact, a retrospective cohort study of 8020 Japanese adults found that persistent NAFLD was associated with an increased risk of developing subclinical carotid atherosclerosis, and that this association was largely explained by coexisting cardiometabolic risk factors. Consistently, a small randomized clinical trial, by evaluating the effect of a 18-mo treatment with either omega-3 fatty acids or placebo on the carotid intima-media thickness (IMT) progression, found that improvement in two markers of NAFLD severity was independently associated with decreased carotid IMT progression.

**Pathogenic mechanisms of T2D and CVD in NAFLD**

T2D in NAFLD: Via ectopic fat storage at multiple organ sites, insulin resistance (IR) is a key pathogenic determinant of T2D development in predisposed individuals with NAFLD. In particular, IR results from storage of ectopic fat in the liver and skeletal muscles owing to long-standing excess of energy supply and subsequent infiltration of macrophages into white adipose tissue.

Recent research focused on the complex and bidirectional relationship between IR and NAFLD. On the one hand, IR is an established risk factor of NAFLD,
which occurs owing to unopposed lipogenic pathways being triggered by IR via multiple transcription factors, such as carbohydrate-responsive element-binding protein, liver X receptors, sterol regulatory element-binding protein 1C and upstream stimulatory factors[92]. On the other hand, NAFLD per se is a major determinant of hepatic IR. Evidence for this notion is that in obese T2D patients the presence of NAFLD is associated with more severe athrogenic dyslipidaemia, hyperinsulinaemia and IR in the adipose tissue and the liver compared to NAFLD-free control subjects[93]. A recent study on the molecular effectors of NAFLD-associated IR[94] has shown that fatty liver induce local and systemic chronic inflammation and IR via an altered protein secretory profile, notably including excess fetuin B, and that the prevention of fatty liver is a rational target for reducing the development of impaired glucose disposal in over-nourished individuals. Consistently, strategies aimed at reducing the development of fatty liver via antisense oligonucleotides against β-catenin may protect mice from diet-induced fatty liver and hepatic and peripheral IR[95].

In the setting of obesity or T2DM/pre-diabetes, the presence of NAFLD often develops in concert with homologous fatty changes of the pancreas[96-101]. Nonalcoholic fatty pancreas (NFP) may be diagnosed by imaging techniques[102], and it is common in the general population[99]. The role of NAFp as a pathogenic mediator for the association between NAFLD and T2D risk has recently been reviewed[103-105].

CVD in NAFLD: In principle, the increased CVD risk seen in patients with NAFLD may result from a shared pathophysiologic background, such as systemic IR and MetS. Such a view, however, would conflict with those studies reporting that NAFLD per se, regardless of coexisting MetS features, exposes to excess CVD risk[87]. Consistently, patients with more "severe" NAFLD are exposed to an increased risk of fatal and non-fatal CVD events compared to NAFLD-free controls[88]. In agreement, NASH, rather than simple steatosis, is associated with endothelial damage and over-expression of multiple atherogenic mediators and regulators of blood pressure[106]. Collectively, these data would support that NASH, as opposed to simple steatosis, is associated with a higher CVD risk. However, this conclusion needs to be further confirmed by future larger prospective studies.

Consistent with the notion reported above, the higher CVD risk seen in patients with NAFLD may result from increasing fibrosis stage, steatosis grade or oxidative stress[89]. Two studies indirectly confirmed this contention. The first study found that both all-cause and CVD mortality were higher especially in NAFLD patients with coexisting MetS features; conversely, the risk of mortality of metabolically-normal NAFLD patients was similar to that of the cohort without liver disease[77]. The second study found that the MetS-associated NAFLD was associated with a higher risk of CVD, T2D and increased cardiac mass, whereas NAFLD without MetS [i.e., a condition that was more frequently associated with the 1148M variant of the patatin-like phospholipase domain-containing 3 gene (PNPLA3) polymorphism] was not[107].

Evidence for fibrosis stage playing a role in CVD risk derives from a cross-sectional study conducted in 1874 healthy European adolescents belonging to the general population. In that study, NAFLD individuals had more advanced non-invasively assessed liver fibrosis and worse cardiometabolic risk profiles independent of potential confounders[108]. Increasing liver fat content is also associated with worsening athrogenic dyslipidaemia and dysglycaemia; accordingly, it can reasonably be hypothesized that the quantity of fatty liver may dictate the risk of cardiometabolic outcomes in patients with NAFLD[109]. Consistent with this hypothesis, a recent cross-sectional study reported that, independent of NASH, increased liver fat content was associated with increased rates of MetS features in NAFLD patients[110].

Given that free fatty acids may induce systemic/hepatic IR, oxidative stress and increased synthesis of pro-thrombotic markers in cultured human hepatocytes[111], it can also be speculated that increased oxidative stress may be a critical contributor to CVD risk seen in NAFLD patients. Consistently, NASH was associated with increased oxidative stress and subclinical atherosclerosis in a recent study[112].

Finally, it is conceivable that also the chemical nature of hepatic fat content may play a role in the link between NAFLD and CVD risk. A study reported that three chemical compounds (11,12-dihydroxy-eicosatetraenoic acid, 13,14-dihydro-15-keto prostaglandin D2 and 20-carboxy arachidonic acid) are more abundant in NASH than in simple steatosis[133]. Moreover, analysis of the human hepatic lipidome showed that similar increases in liver fat content and NASH were associated with a metabolically harmful saturated, ceramide-enriched liver lipidome in “MetS-related NAFLD” but not in “PNPLA3-related NAFLD”, accounting for the finding that the former, rather than the latter, was associated with an increased risk of T2D and CVD[114].

HCV INFECTION

Epidemiology, risk factors and natural history of HCV infection

The worldwide prevalence of HCV infection approximates 1.6%, affecting about 115 million individuals, 80 million of whom are deemed to be viremic[115]. Globally, the G1 genotype is the most common and accounts for roughly one in two of all HCV infections in adults, followed by G3, G2, G4, G6, and G5 genotypes[113].

Traditional risk factors for HCV infection are: assumption of intravenous and intranasal illicit drugs; hemodialysis; cancer; paid blood donations; having
received blood products prior to 1990; high-risk sexual behavior, tattoos or body piercings, working in health care[116]. Presently, in developed countries, the majority of new HCV infections are observed in individuals who inject drugs and in men who have sex with men[116].

Three to four million people are newly infected annually and approximately 350000 people per year die from HCV-related causes. HIV-HCV co-infected individuals sum up to approximately 25000000 worldwide, half of whom belonging to special populations, such as drug injectors[117].

Given that chronicity is the major complication of acute HCV infection, which can lead to many serious liver-related and extra-hepatic outcomes, HCV to date is a significant global public health burden[118].

Over the last few years, the advent of new direct antiviral agents (DAA) has revolutionized the HCV treatment by increasing sustained viral response (SVR) rates from approximately 50% to > 90%. Given that SVR plays a key role in HCV natural history, a multicenter observational study recently found that the survival rates of HCV-related cirrhotic patients who had attained SVR were essentially similar to those in the general population, justifying DAA treatment being administered as earliest as possible to achieve the maximal benefit in HCV-related, compensated cirrhosis[119].

Epidemiological evidence for an association of HCV infection with T2D
HCV is a systemic disease featuring a variety of extra-hepatic manifestations, among which T2D plays a leading role[60,120,121]. Consistently, T2D is the second most prevalent extra-hepatic manifestation, affecting up to 15% of HCV-infected patients[122].

Several cross-sectional studies have shown that patients with HCV-related cirrhosis have a higher prevalence of T2D than those with cirrhosis unrelated to HCV infection[123-125]. Similar results have also been reported in the setting of liver transplantation[126-129], and in patients with all stages of chronic HCV, irrespective of the presence of cirrhosis, suggesting that the connection of HCV infection with IR/T2D was independent of the stage of liver disease[130-136]. A cross-sectional study investigating the relationship between HCV and T2D at the population level showed that T2D occurred more often in HCV-infected persons aged more than 40 years[137]. Consistently, other cross-sectional studies, involving T2D patients, showed that these patients had an increased prevalence of HCV infection[138-140].

Stronger evidence for a possible causal link between HCV and T2D came from longitudinal studies and meta-analyses. A United States prospective case-cohort study showed that pre-existing HCV infection increased the risk of new-onset T2D in persons with coexisting T2D risk factors[141]. A subsequent community-based longitudinal study, involving 4958 non-diabetic Taiwanese individuals, confirmed a significant temporal relationship between prior HCV infection and risk of new-onset T2D[142]. A recent meta-analysis of 31 studies (involving a total of 10388 T2D cases among 61843 HCV individuals and 42358 T2D cases among 202130 HCV-free controls) found that the pooled estimates for odds ratios for new-onset T2D among individuals with HCV infection were 1.58 (95% CI: 1.30-1.86)[122]. These findings are strikingly similar to the results of a previous meta-analysis that showed an approximately 1.7-fold excess risk of new-onset T2D in HCV-infected cases as compared to non-infected controls[143].

Interestingly, a recent study has estimated that the direct medical costs associated with HCV-related T2D were 443 million dollars yearly in the United States, making T2D the most expensive extra-hepatic complication of HCV[122]. Moreover, in patients with HCV, the coexistence of T2D is strongly associated with an increased risk of liver fibrosis progression[132,144-148] and cirrhosis and HCC development[149-152], poor liver-related outcomes[152], lower response rates to peginterferon/ribavirin treatment[146,153-155], and may also partly account for the increased CVD risk[156,157].

Given the substantial health and economic burden of T2D among patients with HCV, treatment strategies aimed at eradicating HCV should also consider the potential benefits in terms of T2D prevention/resolution. Of note, studies have shown that HCV clearance with interferon-based treatment regimens may improve IR and pancreatic beta cell function[158,159], reduce T2D development[160], and improve renal and CVD outcomes[161,162]. Although new DAs allow HCV eradication in the vast majority of HCV patients, little is currently known on the effects of DAs on glucose metabolism[163]. One study showed that SVR obtained with the first-wave protease inhibitor telaprevir was associated with IR improvement[164]. Moreover, preliminary studies showed that DAs significantly reduced plasma glucose and hemoglobin A1c (HbA1c) levels in both HCV patients with and without T2D[165,166].

Epidemiological evidence for an association of HCV infection with CVD
HCV has been isolated from the myocardium of patients with myocarditis and dilated cardiomyopathy and from carotid atherosclerotic plaques, suggesting a direct role of HCV in cardiac dysfunction and accelerated atherogenesis[167-170]. Moreover, a higher prevalence of traditional CVD risk factors and MetS features, such as IR/T2D and fatty liver, have been reported in patients with HCV compared to uninfected controls[171-173]. A growing body of evidence also identifies HCV infection as a potential risk factor for subclinical and clinical CVD complications[156,157].

A proof-of-concept study among 217 Japanese HCV-positive patients without overt CAD demonstrated that myocardial perfusion defects, as detected by scintigraphy, are almost universal in HCV patients, are associated with liver disease activity and HCV-
RNA levels, and improve following viral eradication[172]. Moreover, functional and morphological myocardial changes (as assessed by cardiac magnetic resonance) are common among HCV patients with end-stage liver disease[173]. A population-based cohort study showed that HCV-infected patients have a higher arterial stiffness than HCV-negative control subjects[174]. In addition, multiple cross-sectional studies, which examined carotid atherosclerosis, provided further strong evidence of a relationship between HCV and subclinical atherosclerosis[156,176,178]. Of note, a recent meta-analysis confirmed an association between HCV infection and carotid atherosclerosis[157]. The severity of hepatic steatosis and fibrosis and HCV viral load are among the strong predictors of carotid atherosclerosis[157,178,179].

Importantly, HCV infection is also associated with increased CVD morbidity and mortality. A large study conducted among US Veterans showed that, despite a more favorable cardio-metabolic risk profile, HCV-infected patients had a 1.25-fold higher risk of CAD than uninfected controls[180]. Similarly, a recent Taiwanese community-based study showed that HCV was significantly associated with ischemic electrocardiogram findings[181], and a United States population study found a significant association between HCV infection and the risk of congestive heart failure[182]. Several case-control studies subsequently confirmed that HCV infection predicted CAD and was independently associated with a greater severity of coronary stenoses[183-186], also among HCV-HIV co-infected patients and dialysis patients[187,188].

Similar findings were reported from studies evaluating the risk of cerebro vascular events among HCV patients[189-191]. For instance, a large Taiwanese population-based cohort study showed that HCV-infected patients had a 1.3-fold higher risk of ischemic stroke than HCV-free individuals[189]. Of note, HCV eradication (with interferon-based therapy) has reduced the long-term risk of ischemic stroke and acute coronary syndrome in HCV patients[191,192,193].

A recent meta-analysis of 8 observational studies confirmed that HCV infection was associated with increased CVD morbidity, and the strength of this association was similar for CVD and cerebro vascular events[157].

Worryingly, some studies also suggested a significant association between HCV and cerebral hemorrhages[192,193], and a recent large Taiwanese cohort study extended the association between HCV and atherosclerosis by showing that HCV-infected patients had an increased risk of peripheral artery disease compared to non-HCV control subjects[194].

Finally, a number of studies reported that HCV infection was independently associated with an increased CVD mortality[157,195-197] also in HIV co-infected patients and in dialysis patients[196,199].

Pathogenic mechanisms of T2D and CVD in HCV infection

A significant proportion of HCV-related morbidity and mortality may result from the coexistence of T2D and CVD in the development of which HCV may play a pathogenic role; moreover, HCV may also induce fatty liver, which in its turn, further increases CVD risk[200], especially in those with T2D and hypertension[157].

The main reason why HCV is a "successful pathogen" is that it exploits host’s metabolism to build up viral particles. In so doing, HCV infection has developed a set of metabolic abnormalities collectively referred to as “hepatitis C-associated dysmetabolic syndrome” (HCADS)[171]. HCADS includes fatty liver, hyperuricemia, hypcholesterolaemia, IR, hypertension and visceral overweight/obesity. Such metabolic disorders may best be interpreted as a “Darwinian strategy”, favoring HCV survival at the expense of the host’s metabolism. The finding of expanded visceral adipose tissue in HCV-infected patients is consistent with the hepatic and extra-hepatic origins of IR discussed above, and prompts further research regarding the potential ability of HCV to infect the adipose tissue[60].

Similar to the pathogenic model of T2D developing in the setting of NAFLD, HCV may exacerbate IR eventually leading to dysfunction/damage of pancreatic beta cells and development of overt T2D in most patients over time[121]. Conversely, HCV eradication may result in IR improvement, although definite evidence for this conclusion is eagerly awaited[201].

HCV antigens, notably including the core protein, play a key role in determining IR by interfering with the AKT signaling pathway, through the action of both pro-inflammatory cytokines [e.g., tumor necrosis factor-alfa and interleukin-6 (IL-6)] and suppressors of cytokine signaling[202]. The site of IR is not only hepatic but also extra-hepatic, mainly in the skeletal muscles, correlates with subcutaneous, rather than visceral adiposity, and is independent of liver fat content[60,171].

The role of specific viral genotypes in the development of IR is also increasingly appreciated. An extensive French study reported that IR was significantly associated with G1 and G4 genotypes, high HCV-RNA viral load and significant hepatic fibrosis, irrespective of fatty liver[134].

T2D and IR are strong predictors of faster progression of liver fibrosis and impaired response rates to HCV treatment[153,203]. Patients with HCV-related cirrhosis and T2D have an increased susceptibility to developing hepatic encephalopathy and HCC; moreover, concurrent T2D accounts for a persistently higher HCC risk even in those patients attaining SVR[204-206]. Theoretically, in patients with chronic HCV infection, a better glycemic control could improve the prognosis and the response rate to HCV treatment, although direct evidence for this is limited.

Beneficial effects of antiviral treatment on IR and T2D are increasingly identified. By evaluating paired
pre-treatment and post-treatment HOMA-estimated IR measurements in 1038 non-diabetic HCV patients, a study found that SVR was associated with a significant IR improvement in HCV patients infected with G1 genotype (but not in those infected with G2/3); IR improvement was independent of body weight, serum transaminase and lipid level changes, suggesting that G1 genotype might directly promote IR, independent of host metabolic factors, and might be improved following HCV eradication[207].

A preliminary clinical trial of 29 patients with T2D who were receiving different interferon-free regimens reported that fasting glucose and HbA1c levels were significantly reduced by the treatment, irrespective of the DAA used, HCV genotype, body weight and HIV status. Consistently, the dosages of hypoglycemic drugs were reduced in about a quarter of these patients[208-210].

T2D is not the only metabolic disease observed in the setting of HCV infection. Over time, several metabolic features of what is now alluded to as the HCADS have been increasingly identified. The HCV-related fatty liver, which is one of such features, was first identified as a distinct disease entity. Data comparing fatty liver both in the viral setting and NAFLD suggest that IR is a prominent feature specifically associated with HCV infection[7].

All HCV genotypes share multiple “NAFLD-like” steatogenic mechanisms, such as increased availability of lipogenic substrates and de novo lipogenesis; decreased oxidation of fatty substrates and export of fatty substrates. However, G3 genotype induces more prominent derangements in molecular mediators of steatogenesis (e.g., microsomal triglyceride transfer protein; peroxisome proliferator-activated receptor alpha; sterol regulatory element-binding proteins and phosphatase and tensin homologue), thus amplifying those steatogenic mechanisms, which also take place in NAFLD. As a result of this, fatty liver is more frequently associated with G3 genotype and is, therefore, designated as “viral fatty liver” as opposed to fatty liver occurring in HCV non-3 genotypes and particularly G1 genotype, which is more closely associated with host’s features[217,203,208-210].

Among the various features of HCADS, HCV-related fatty liver has a distinct, prominent clinical impact in as much as it accelerates hepatic fibrogenesis; impairs the response rates to interferon-alpha and ribavirin treatments; increases the risk of developing HCC and predisposes to accelerated atherogenesis[33,156,217,179].

HIV INFECTION

Epidemiology, risk factors and natural history of HIV infection
Recent UNAIDS estimates indicate than in 2015 there were approximately 2.1 million new cases of HIV infections worldwide, adding up to a total of approximately 37 million people already living with HIV[211]. Against these dramatic features, over the last 15 years, HIV medicine gained impressively positive results in terms of improved life expectancy for HIV-infected adults in Western countries. This finding results from major changes in the natural history of HIV disease and in the efficacy of anti-retroviral therapy (ART)[212,213]. Scale-up of the ART is on a fast-track trajectory that has surpassed expectations. Global coverage of ART reached approximately 46% at the end of 2015 (with the greatest gains in the world’s most affected region, Eastern and Southern Africa)[214]. Several recent studies have suggested that the life expectancy of HIV-infected patients may approach that of the general population, particularly among patients who initiated ART at earlier disease stages[215]. Simultaneously, HIV seroconversion among older age persons is increasingly recognized, partly due to a lower perception of sexual risk in older people[216]. As a result of these changes, what we observe is that HIV-infected persons are more likely to be older and have an increased burden of age-related comorbidities compared to persons of a similar age who have been infected by HIV more recently[217].

While this “graying” of the HIV-infected population is to be welcomed as an indication of improved treatment and survival rates, the increasing number of older HIV-infected patients with increased rates of comorbidities presents new challenges for patient care. Cardio metabolic complications, such as CVD, atherogenic dyslipidemia and glucose intolerance/T2D, are very common in older HIV-infected patients, and justify the onset of multidisciplinary metabolic clinics for the management of patients with chronic HIV-related co-morbidities[218].

Epidemiological evidence for an association of HIV infection with T2D
Patients with HIV are at higher risk of new-onset T2D compared to the general adult population[219]. The reasons for this increased T2D risk are not entirely understood, but may include the use of some ARTs[220], the presence of HCV co-infection[221], and the HIV-induced systemic chronic inflammation[222,223]. Untreated HIV is associated with higher levels of multiple pro-inflammatory biomarkers, and initiation of ART results in a decline, but does not normalize plasma pro-inflammatory biomarkers[224]. The occurrence of IR, which is causally associated with the development of T2D, was one of the first metabolic disorders associated with HIV disease and treatments[225].

T2D development can be, at least in part, linked to an underlying chronic inflammation. Population-based studies suggested that higher levels of IL-6 and C-reactive protein (CRP) are independently associated with an increased risk of new-onset T2D[226]. Cross-sectional studies also reported a significant and positive association between plasma CRP levels and IR in
non-diabetic individuals\textsuperscript{227}. Moreover, it has been shown that in healthy volunteers the administration of subcutaneous recombinant human IL-6 induced a dose-dependent increase in fasting glucose levels\textsuperscript{228}. A recent retrospective cohort study involving 3695 non-diabetic participants, who took ART and were followed-up for an average of 4.6 years, found that higher circulating CRP and IL-6 levels were significantly associated with an increased risk of new-onset T2D. Other common risk factors for new-onset T2D in this cohort of HIV-infected patients were older age, higher body weight, co-infection with hepatitis B or C, non-smoking status and use of lipid-lowering drugs. All these findings suggest that systemic chronic inflammation may contribute to the development of T2D in patients with HIV\textsuperscript{229}.

**Epidemiological evidence for an association of HIV infection with CVD**

The burden of CVD is increased in HIV-infected patients\textsuperscript{230}. The investigators of the Veterans Aging Cohort Study (VACS) recently analyzed the data collected in 82459 Veterans who were followed-up for a mean period of 5.9 years. When these VACS participants were stratified by the presence or absence of traditional CVD risk factors, HIV-infected patients without risk factors had a twofold greater risk of incident acute myocardial infarction compared to uninfected control individuals and their risk steeply increased with each additional CVD risk factor added\textsuperscript{231}.

Although CVD has become a major cause of mortality among HIV-infected patients, outnumbering those figures expected based on the high prevalence of CVD risk factors observed in this patient population, controversy still exists regarding the underlying pathogenic mechanisms of accelerated atherosclerosis in HIV.

Such an increased CVD risk may be likely due to both a direct role of HIV and the dysregulated immunological responses caused by chronic HIV infection\textsuperscript{231-233}. Tight control of HIV replication and maintenance of a good CD4 count seem to protect from the risk of incident CVD events. However, there is conflicting evidence regarding the association of the CD4 cell count and the HIV-RNA levels with the risk of CVD\textsuperscript{234,235}. The trans-activator of transcription (Tat), i.e., a regulatory protein that enhances the efficiency of viral transcription, may represent a pathogenic mechanism by which HIV may directly induce accelerated atherogenesis\textsuperscript{236}. Tat induces the expression of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin\textsuperscript{237}, which are associated with an increased incidence of CVD in healthy individuals\textsuperscript{238}. The levels of these circulating endothelial adhesion molecules are markedly increased in HIV-infected patients, and there is a significant relationship of elevated soluble ICAM-1 levels with HIV disease progression and reduced CD4 cell count\textsuperscript{239}. Similarly to Gp120, Tat may also decrease endothelium-dependent vasodilation and nitric oxide synthase secretion in porcine coronary arteries\textsuperscript{240}.

In addition to the above-mentioned humoral effects, cellular immune activation may also play a role in CVD development among HIV-infected patients\textsuperscript{241}. Monocytes are readily infected by HIV and may adhere to the endothelial surface and, eventually, penetrate in the sub-endothelial space and intima\textsuperscript{242}. Furthermore, monocytes expressing CD14\textsuperscript{+} and CD16\textsuperscript{+} are also prone to a greater pro-inflammatory activity once infected by HIV\textsuperscript{243}.

Uncertainty still remains as to the extent to which traditional CVD risk factors, immune risk factors, and non-traditional behavioral risk factors contribute to CVD development in HIV-infected individuals. Importantly, the circulating monocyte activation marker sCD163 is associated with high-risk morphology coronary atherosclerotic plaques and arterial inflammation\textsuperscript{244,245}.

Finally, in specific populations of HIV patients, non-traditional behavioral risk factors, such as cocaine use, may also contribute to accelerated atherogenesis via multiple mechanisms\textsuperscript{246}.

**Pathogenic mechanisms of T2D and CVD in HIV infection**

In HIV-infected patients the etiology of CVD and T2D reflects the complex and intertwined interactions of multiple factors present in this particularly high-risk patient population, such as the higher prevalence of traditional and non-traditional CVD risk factors, the effects of HIV infection, and the effects of ARTs. In this context, it is reasonable to assume that fatty liver itself might also play a pathogenic role in the development of CVD in patients with HIV.

The adverse effect of the HIV infection on the re-distribution of adipose tissue is known as "lipohypertrophy", which mainly consists of the expansion of ectopic fat depots such as abdomen, liver, doro-cervical region (sometimes with buffalo hump), trunk and heart, which may all contribute to the development of T2D and other MetS features\textsuperscript{247}.

In patients in whom fatty liver occurs in the context of HIV and/or HCV (i.e., VAFLD), the development of fatty liver may result from a complex interplay between host and viral factors, such as sex, lifestyle habits, IR, MetS, HCV genotype, viral load and ART use\textsuperscript{210,248}. In HIV-infected patients, the potential steatogenic effect of ARTs remains controversial\textsuperscript{249,250}. Although VAFLD is highly prevalent in HCV/HIV-coinfected patients\textsuperscript{251}, the natural history of fatty liver observed in these patients remains incompletely understood. A recent study reported that fatty liver was a precursor lesion to hepatic fibrosis\textsuperscript{252}, suggesting that the effective management of fatty liver might also result in the reduction of hepatic fibrosis progression in patients
with HCV/HIV co-infection. Moreover, IR is a predictor of reduced SVR in both HCV-monoinfected and HCV/HIV-coinfected patients. All these findings further underline the importance of improving our understanding of the independent contribution of fatty liver to the pathophysiology of CVD and T2D in this patient population.

To date, there are very limited data regarding the clinical, biochemical and liver histological features of HIV-related VAFLD; moreover, it remains uncertain whether VAFLD differs in terms of clinical presentation and histological severity from primary NAFLD. A small cross-sectional study showed that, compared to age- and sex-matched patients with primary NAFLD, those with HIV-related VAFLD not only had a more severe metabolic profile but also more severe forms of liver disease.

Presently, large prospective studies on VAFLD in HIV are lacking. A very small series of 10 HIV mono-infected VAFLD patients, who were treated either with maraviroc (MRV) plus atazanavir (n = 7) or with vitamin E (n = 3), found that at baseline the histologic degree of hepatic steatosis was 20% and decreased to approximately 10% after treatment. The extent of steatosis improved in all patients, except for two patients who gained body weight. A reduction in hepatic fat content assessed histologically and with magnetic resonance at 48 wk was found both in the atazanavir/MRV and, to a lesser extent, in the Vitamin E treatment groups. The results of this preliminary study suggest a possible role of MRV in the treatment of fatty liver in HIV-infected patients (Guaraldi G et al., unpublished data). However, future large randomized clinical trials are needed to confirm these findings.

As lipodystrophy may predispose HIV-infected patients to develop T2D and other MetS features, new prevention and management strategies should be evaluated. For example, avoidance of some ART regimens, containing stavudine and zidovudine, might help in preventing the development of lipoatrophy, but no strategies have proven effective against lipohypertrophy. For patients with established lipoatrophy, switching from ART regimens, containing either stavudine or zidovudine, to an alternative ART regimen could be an empirical choice. Tesamorelin, a synthetic growth-hormone-releasing analogue, has been approved for the treatment of lipohypertrophy. This drug may reduce both abdominal visceral adiposity and liver fat content, but its long-term effects on the risk of T2D and CVD remain uncertain.

**CONCLUSION**

In this narrative review, we have tested the hypothesis that fatty liver represents a shared pathogenic mechanism for the development of CVD and T2D not only in patients with NAFLD but also in those with chronic HCV or HIV infections. To do so, we have followed an innovative multidisciplinary comparative approach, by extending the widely accepted comparison of NAFLD with chronic HCV infection to HIV infection.

What we have found is that, the published data are biologically consistent in identifying NAFLD as a major player in the development of T2D and CVD (as schematically shown in Figure 1). Indeed, the clinical burden of NAFLD is not only restricted to liver-related morbidity or mortality, but there is now growing evidence that NAFLD is a multisystem disease, affecting multiple extra-hepatic organs and regulatory, inflammatory and metabolic pathways. Strong evidence indicates that CVD complications frequently dictate the clinical outcomes of NAFLD patients and, therefore, screening for CVD is mandatory in all patients with NAFLD, at least by utilizing a detailed risk factor assessment. Furthermore, convincing evidence also supports a link between NAFLD and the risk of new-onset T2D. Collectively, accumulating evidence suggests that NAFLD is not a simple marker of CVD and T2D, but also plays a part in the pathophysiology of these cardiometabolic complications. NAFLD, especially in its necro-inflammatory variant (NASH), exacerbates systemic/hepatic IR, predisposes to atherogenic dyslipidaemia, and releases several pro-inflammatory, pro-coagulant, pro-oxidant and pro-fibrogenic mediators that play important roles in the development of CVD and T2D.

Likewise, HCV and HIV are two globally prevalent pathogens and leading causes of mortality and morbidity worldwide. Patients with chronic HCV infection or HIV infection are at higher risk of developing T2D and CVD. Interestingly, fatty liver is often observed in patients with chronic HCV or HIV infections and a wide array of similarities with NAFLD further supports a link of HCV or HIV infections with the risk of T2D and CVD.

On the grounds of data examined here, it is therefore reasonable to assume that fatty liver might be a shared pathological condition which plays a key role in the development of T2D and CVD not only in patients with NAFLD but also in those with chronic HCV or HIV infections. However, further research is required to further corroborate the prognostic role of fatty liver per se in the development of T2D and CVD in patients with chronic HCV or HIV infections, and to better elucidate the differences and similarities between NAFLD and VAFLD. Moreover, it remains uncertain whether specific algorithms for CVD/T2D risk assessment should be implemented and validated both in patients with NAFLD and in those with VAFLD.

In the meantime, the findings of this review may disclose new avenues in the clinical and research arenas. Our findings also pave the way for planning future prospective and intervention studies of clinical relevance because, for example, with the success of ARTs, HIV-related co-morbidities, like T2D and CVD,
are of increasing concern.[263]

REFERENCES

1 Petäjä EM, Yki-Järvinen H. Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic Review. Int J Mol Sci 2016; 17 [PMID: 27128911 DOI: 10.3390/ijms17050633]

2 Lonardo A, Lombardini S, Scaglioni F, Carulli L, Ricchi M, Ganazzi D, Adinolfi LE, Ruggiero G, Carulli N, Loria P. Hepatic steatosis and insulin resistance: does etiology make a difference? J Hepatol 2006; 44: 190-196 [PMID: 16168516 DOI: 10.1016/j.jhep.2005.06.018]

3 Ballestri S, Nascimbeni F, Romagnoli D, Lonardo A. The independent predictors of non-alcoholic steatohepatitis and its individual histological features: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res 2016; 46: 1074-1087 [PMID: 26785389 DOI: 10.1111/hepr.12656]

4 Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, Roverato A, Guaraldi G, Lonardo A. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol 2016; 31: 936-944 [PMID: 26667191 DOI: 10.1111/jgh.13264]

5 Adinolfi LE, Rinaldi L, Guerrera B, Restivo L, Marrone A, Giordano M, Zampino R. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. Int J Mol Sci 2016; 17: [PMID: 27231906 DOI: 10.3390/ijms17050633]

6 Guaraldi G, Stentarelli C, Orlando G, Zona S, Carli F, Ballestri S, Lonardo A, Squillace N, Loria P. Nonalcoholic fatty liver disease in HIV-infected persons: epidemiology and the role of nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2010; 53: 278; author reply 278-281 [PMID: 20104126 DOI: 10.1097/QAI.0b013e3181c90bed]

7 Guaraldi G, Stentarelli C, Orlando G, Zona S, Carli F, Ballestri S, Lonardo A, Squillace N, Loria P. Nonalcoholic fatty liver disease in HIV-infected persons: epidemiology and the role of nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2010; 53: 278; author reply 278-281 [PMID: 20104126 DOI: 10.1097/QAI.0b013e3181c90bed]

8 Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Fatty liver increases the risk of type 2 diabetes and cardiovascular disease.
Larondo A et al. Fatty liver increases the risk of type 2 diabetes and cardiovascular disease.

66 Soo koain S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008; 49: 600-607 [PMID: 18672311 DOI: 10.1016/j.jhep.2008.06.012]

67 Mantovan A, Ballestri S, Larondo A, Targar G. Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2016; 61: 1246-1267 [PMID: 26809873 DOI: 10.1007/s10620-016-4040-6]

68 Pais R, Giralt P, Khan JF, Rosenbaum D, Housse C, Pouyart T, Ratziu V. Fatty liver is an independent predictor of early carotid atherosclerosis. J Hepatol 2016; 65: 95-102 [PMID: 27129386 DOI: 10.1016/j.jhep.2016.02.023]

69 Amapuro J, Gallego-Duran R, Romero-Gomez M. Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. Rev Esp Enferm Dig 2015; 107: 10-16 [PMID: 25603326]

70 Targar G, Bertolini L, Rodella S, Tessari R, Zenari L, Lippi G, Aragco G. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007; 30: 2119-2121 [PMID: 17519430 DOI: 10.2337/db07-0349]

71 Jepsen P, Vilstrup H, Møller-Kjaer L, Thaulstrup AM, Olsen JH, Baran JA, Sorensen HT. Prognosis of patients with a diagnosis of fatty liver--a registry-based cohort study. Hepatogastroenterology 2003; 50: 2101-2104 [PMID: 14696473]

72 Targar G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Aragco G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-1218 [PMID: 17277038 DOI: 10.2337/db06-703]

73 Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, Kawaiho Y, Yoshida N, Suetsugu A, Kato T, Okuda J, Ida K, Yoshikawa T. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. J Jpn Gastroenterol 2007; 13: 1579-1584 [PMID: 17461452]

74 Haring R, Wallaeschfus H, Nauck M, Dör M, Baumeister SE, Volzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 2009; 50: 1403-1411 [PMID: 19670414 DOI: 10.1002/hep.23135]

75 Zhou YJ, Li YY, Nie YQ, Huang CM, Cao CY. Natural course of nonalcoholic fatty liver disease in southern China: a prospective cohort study. J Dig Dis 2012; 13: 153-160 [PMID: 22356310 DOI: 10.1111/j.1751-2980.2011.00571.x]

76 Trepparotet S, Leveque S, Adams LA, Lindor KD, St Sauver J, Angulo P. The Framingham risk score and heart disease in nonalcoholic fatty liver disease patients undergoing coronary angiogram: A prospective cohort study. Hepatology 2016; 63: 754-763 [PMID: 24606278 DOI: 10.1002/hep.28253]

77 Adams LA, Lymp JF, St Sauver SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121 [PMID: 16012941]

78 Rafiq N, Bai C, Fang Y, Shrishid M, McCullough A, Gramlich T, Younossi ZM. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-238 [PMID: 19049831 DOI: 10.1016/j.cgh.2008.11.005]

79 Söderberg C, Stål P, Askling J, Ljungman G, Lindberg M, Bennet C, Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602 [PMID: 20014114 DOI: 10.1002/hep.23314]

80 Targar G, Byrne CD, Larondo A, Zoppini G, Barbucii C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol 2016; 55: 589-600 [PMID: 27212244 DOI: 10.1016/j.jhep.2015.05.013]

81 Sinn DH, Cho SJ, Gu S, Seong D, Kang D, Kim H, YI BK, Paik SW, Guallar E, Cho J, Owak GY. Persistent Nonalcoholic Fatty Liver Disease Increases Risk for Carotid Atherosclerosis. Gastroenterology 2016; 151: 481-488.e1 [PMID: 27283259 DOI: 10.1053/j.gastro.2016.06.001]

82 Bhatia L, Scorletti E, Curzen N, Clough GF, Calder PC, Byrne CD. Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression. Atherosclerosis 2016; 246: 13-20 [PMID: 26748347 DOI: 10.1016/j.atherosclerosis.2015.12.028]

83 Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest 2016; 126: 12-22 [PMID: 26727229 DOI: 10.1172/JCI77812]

84 Wang Y, Viscarra J, Kim SJ, Sul HS. Transcriptional regulation of hepatic lipogenesis. Nat Rev Mol Cell Biol 2015; 16: 678-689 [PMID: 26490400 DOI: 10.1038/nrm4074]

85 Lomaraco N, Bril F, Portillo-Sanchez P, Ortiz-Lopez C, Orsak B, Bismarchi D, Lo M, Summan A, Weber MH, Cusi K. Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes. Diabetes Care 2016; 39: 632-638 [PMID: 26861926 DOI: 10.2337/dci15-1876]

86 Mee RC, Hoy AJ, Morris A, Brown RD, Lo JC, Burke M, Gooe RJ, Kingwell BA, Kraakman MJ, Febbraio MA, Greve JW, Renss SS, Molley MP, Lancaster GI, Bruce CR, Watt MJ. Fettuin B Is a Secreted Hepatocyte Factor Linking Steatosis to Impaired Glucose Metabolism. Cell Metab 2015; 22: 1078-1089 [PMID: 26603189 DOI: 10.1016/j.cmet.2015.09.023]

87 Popov VB, Jornayvaz FR, Akglu EO, Kand A, Jurczak MJ, Zhang D, Abudukadir A, Majumdar SK, Guigni B, Petersen KF, Manchep VM, Bhanot S, Shulman GI, Samuel VT. Generation-antisense oligonucleotides against β-catenin protect mice against diet-induced hepatic steatosis and hepatic and peripheral insulin resistance. FASEB J 2016; 30: 1207-1217 [PMID: 26644352 DOI: 10.1096/fj.15-27199]

88 Sepe PS, Ohri A, Sanaka S, Berzin TM, Sekhon S, Bennett
Lorado A et al. Fatty liver increases the risk of type 2 diabetes and cardiovascular disease

G, Mehta G, Chutani R, Kane R, Pleskov D, Sawhney MS. A prospective evaluation of fatty pancreas by using EUS. *Gastrointest Endosc* 2011; 73: 987-993 [PMID: 21525167 DOI: 10.1016/j.gie.2011.01.015]

97 Ou HY, Ou CY, Yang YC, Chen MF, Chang CJ. The association between nonalcoholic fatty liver disease and diabetes. *PLoS One* 2013; 8: e62561 [PMID: 23671610 DOI: 10.1371/journal.pone.0062561]

98 Wu WC, Wang CY. Association between non-alcoholic fatty pancreatic disease (NAFPD) and the metabolic syndrome: case-control retrospective study. *Cardiovasc Diabetol* 2013; 12: 77 [PMID: 23688357 DOI: 10.1186/1475-2801-12-77]

99 Wang CY, Ou HY, Chen MF, Chang TC, Chang CJ. Enigmatic ectopic fat: prevalence of nonalcoholic fatty liver disease and its associated factors in a Chinese population. *J Am Heart Assoc* 2014; 3: e000297 [PMID: 24572250 DOI: 10.1161/ JAHA.113.000297]

100 Uygun A, Kadayıfci A, Demirci H, Saglam M, Sakın YS, Ozturk K, Polat Z, Karşılıgolu Y, Bolu E. The effect of fatty pancreas on serum glucose parameters in patients with nonalcoholic steatohepatitis. *Eur J Intern Med* 2015; 26: 37-41 [PMID: 25491010 DOI: 10.1016/j.ejim.2014.11.007]

101 Yamazaki H, Tsuoya T, Katunuma A, Kodama Y, Tauchi S, Dohke M, Maguchi H. Lack of Independent Association Between Fatty Pancreas and Incidence of Type 2 Diabetes: 5-Year Japanese Cohort Study. *Diabetes Care* 2016; 39: 1677-1683 [PMID: 27422578 DOI: 10.2337/dc16-0074]

102 Pezzilli R, Calciulli L. Pancreatic steatosis: Is it related to either obesity or diabetes mellitus? *World J Diabetes* 2014; 5: 415-419 [PMID: 25216389 DOI: 10.4239/wjd.v5.i14.415]

103 Back SH, Kaufman RJ. Endoplasmic reticulum stress and type 2 diabetes. *Ann Rev Biochem* 2012; 81: 767-793 [PMID: 22443930 DOI: 10.1146/annurev-biochem-072909-195555]

104 Loria P, Lonardo A, Anania F. Liver and diabetes. A vicious circle. *Diabetes Care* 2010; 33: 51-64 [PMID: 20332087 DOI: 10.1111/ j.1747-1767.2010.0301.1.x]

105 Sharma RB, Alonso LC. Lipotoxicity in the pancreatic beta cell: not just survival and function, but proliferation as well? *Curr Diab Rep* 2014; 14: 492 [PMID: 24740729 DOI: 10.1007/s11892-014-0492-2]

106 Sookoian S, Gianotti TF, Rosselli MS, Burgueno AL, Castaño GO, Calvaruso V, Aghemo A, Cabibbo G, Viganò M, Boccaccio V, Craxì A, Colombo M, Maisonneuve P. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. *J Hepatol* 2016; 64: 1217-1223 [PMID: 27059129 DOI: 10.1016/j.jhep.2016.01.034]

107 Negro F, Forton D, Craxì A, Sulikowski MS, Feld JJ, Manns MP. Extrapancreatic morbidity and mortality of chronic hepatitis C. *Gastroenterology* 2015; 149: 1345-1360 [PMID: 26319013 DOI: 10.1053/j.gastro.2015.08.035]

108 Lonardo A, Adinolfi LE, Petta S, Craxì A, Loria P. Hepatitis C and diabetes: the inevitable coincidence? *Expert Rev Anti Infect Ther* 2009; 7: 293-308 [PMID: 19344243 DOI: 10.1586/eri.09.3]

109 Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrapancreatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. *Gastroenterology* 2016; 150: 1599-1608 [PMID: 26924097 DOI: 10.1053/j.gastro.2016.02.039]

110 Allison ME, Wreggitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. *J Hepatol* 1994; 21: 1135-1139 [PMID: 7692490]

111 Caronia S, Taylor K, Pagliaro L, Cari C, Palazzo U, Petri J, O’Rahilly S, Shore S, Tom BD, Alexander GJ. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. *Hepatology* 1999; 30: 1059-1063 [PMID: 10498660 DOI: 10.1002/hep.510030416]

112 Zein NN, Abdulkarim AS, Wiesner RH, Egan KS, Persing DH. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. *J Hepatol* 2000; 32: 209-217 [PMID: 10707860]

113 Knobl H, Stagnaro-Green A, Wallenstein S, Schwartz M, Roman SH. Higher incidence of diabetes in liver transplant recipients with hepatitis C. *J Clin Gastroenterol* 1998; 26: 30-33 [PMID: 9492860]

114 Biggam DL, Pennington JJ, Carpenter A, Wanless IR, Hemming AW, Croxford R, Greig PD, Lilly LB, Heathcote JE, Levy GA, Cattral MS. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. *Hepatology* 2000; 32: 87-90 [PMID: 11111444]
Larondo A et al. Fatty liver increases the risk of type 2 diabetes and cardiovascular disease
Lonardo A et al. Fatty liver increases the risk of type 2 diabetes and cardiovascular disease

Studies. *Gastroenterology* 2016; 150: 145-155.e4; quiz e15-16 [PMID: 26386298 DOI: 10.1053/j.gastro.2015.09.007]

158 Kawaguchi T, Ide T, Taniguchi E, Hirano E, Ito M, Sumie S, Nagao Y, Yamagimoto C, Hanada S, Koga H, Sata M. Clearance of HCV improves insulin resistance, betatell function, and hepatic expression of insulin receptor substrate 1 and 2. *Am J Gastroenterol* 2007; 102: 570-576 [PMID: 17222321 DOI: 10.1111/j.1572-0241.2006.01038.x]

159 Conjeeveram HS, Wahed AS, Afdhal N, Howell CD, Everhart JE, Hoofnagle JH. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. *Gastroenterology* 2011; 140: 469-477 [PMID: 21070775 DOI: 10.1053/j.gastro.2010.11.002]

160 Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kamisawa Y, Yatsuki H, Sezaki H, Hosaka T, Hirakawa M, Ikeda K, Kumada H. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. *Hepatology* 2009; 49: 739-744 [PMID: 19127513 DOI: 10.1002/hep.22703]

161 Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, Wu MS, Liu YY, Wu CY. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. *Hepatology* 2014; 59: 1293-1302 [PMID: 24122848 DOI: 10.1002/hep.26892]

162 Hsu YC, Ho HJ, Huang YT, Wang HH, Wu MS, Lin JT, Wu CY. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. *Gut* 2015; 64: 495-503 [PMID: 25398770 DOI: 10.1136/gutjnl-2014-308163]

163 Grasso A, Malfatti F, Testa R. Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C? *World J Gastroenterol* 2013; 19: 6047-6056 [PMID: 24222938 DOI: 10.3748/wjg.v19.i41.6947]

164 Serfaty L, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G, Drenth JP, Lonardo A, Mezzaroma I, Passavanti G, Vittorizzo P, Mastroianni CM, Vullo V. Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents. *Clin Microbiol Infect* 2016; 22: 462.e1-462.e3 [PMID: 26812446 DOI: 10.1111/cmi.12603]

165 Meissner EG, Lee YJ, Osaka K, Szymanska L, Mehta JL. Impact of hepatitis C seropositivity on atherosclerosis and cardiometabolic risk factors. *Gut* 2015; 64: 1437-1440 [PMID: 22387529 DOI: 10.1136/gutjnl-2011-300749]

166 Pavone P, Tieghi D, Ettorre G, Lichtenberg M, Marocco R, Mezzaroma I, Passavanti G, Vittorizzo P, Mastroianni CM, Vullo V. Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents. *Clin Microbiol Infect* 2016; 22: 462.e1-462.e3 [PMID: 26812446 DOI: 10.1111/cmi.12603]

167 Mostafa A, Mohamed MK, Saeed M, Anwar M, Godland I, Coady E, Hamid M, Chaturvedi N. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. *Gut* 2010; 59: 1135-1140 [PMID: 20584782 DOI: 10.1136/gut.2009.202317]

168 Pettit S, Torres D, Fazio G, Cammù C, Cabibi D, Di Marco V, Licitra A, Marchesini G, Mazzola A, Parrinello G, Novo S, Licitra G, Craxì A. Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. *Hepatology* 2012; 55: 1317-1323 [PMID: 22135089 DOI: 10.1002/hep.25508]

169 Adinolfi LE, Restivo L, Zappino R, Guerrera B, Lonardo A, Ruggiero L, Raffauro A, Florio P. Chronic HCV infection is a risk factor of atherosclerosis. *Role of HCV and HCV-related steatosis. Atherosclerosis* 2012; 221: 496-502 [PMID: 22385985 DOI: 10.1016/j.atherosclerosis.2012.01.051]

170 Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. *Clin Infect Dis* 2009; 49: 225-232 [PMID: 19508169 DOI: 10.1086/599371]

171 Lin MS, Guo SE, Chen MY, Huang TJ, Huang JC, Hu JH, Lin YS. The impact of hepatitis C infection on ischemic heart disease via ischemic electrocardiogram. *Am J Med Sci* 2014; 347: 478-484 [PMID: 24335568 DOI: 10.1097/MAJ.0b013e3182558574]

172 Younossi ZM, Zimney E, Shiffman M, Tuller Z, Elsheikh E, Younossi Z, Elsheikh E. Associations of chronic hepatitis C with metabolic and cardiac outcomes. *Aliment Pharmacol Ther* 2013; 37: 647-652 [PMID: 23384408 DOI: 10.1111/apt.12234]

173 Vassalle C, Masini S, Bianchi F, Zucchelli GC. Evidence for association between hepatitis C virus seropositivity and coronary artery disease. *Heart* 2004; 90: 565-566 [PMID: 15084562]

174 Alyan O, Kaouk F, Ordemet O, Devbei B, Astan R, Celebi AS, Ilkay E. Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified Reardon severity score system. *Circ J* 2008; 72: 1960-1965 [PMID: 18957787]

175 Satapathy SK, Kim YJ, Kataria A, Shifteh A, Bhansali R, Cerulli MA, Bernstein D. Higher Prevalence and More Severe Coronary Artery Disease in Hepatitis C Virus-infected Patients: A Case Control Study. *J Clin Exp Hepatol* 2013; 3: 186-191 [PMID: 23554499 DOI: 10.1016/j.jceh.2013.05.004]

176 Pothineni NV, Delongchamp R, Vallurupalli S, Ding Z, Dai Y, Hagedorn CH, Mehta JA. Impact of hepatitis C seropositivity on the risk of coronary heart disease events. *Am J Cardiol* 2014; 114: 1841-1845 [PMID: 25438910 DOI: 10.1016/j.amjcard.2014.09.020]

177 McKibben RA, Haberlen SA, Post WS, Brown TT, Budoff M, Witt MD, Kingsley LA, Palaja FL, Thio CL, Seaberg EC. A Cross-sectional Study of the Association Between Chronic Hepatitis C Virus Infection and Subclinical Coronary Atherosclerosis Among
Participants in the Multicenter AIDS Cohort Study. J Infect Dis 2016; 213: 257-265 [PMID: 26216904 DOI: 10.1093/infdis/jiv936]

Yelken B, Gorgula N, Caliskan Y, Elikin A, Cimen AO, Yazici H, Oflaz H, Turkmen A, Sever MS. Association between chronic hepatitis C infection and coronary flow reserve in dialysis patients with failed renal allografts. Transplant Proc 2009; 41: 1519-1523 [PMID: 19545669 DOI: 10.1016/j.transproceed.2009.03.069]

Liao CC, Su TC, Sung FC, Chou WH, Chen TL. Does hepatitis C virus infection increase risk for stroke? A population-based cohort study. PLoS One 2012; 7: e31527 [PMID: 22366360 DOI: 10.1371/journal.pone.0031527]

Adinolfi LE, Restivo L, Guerrera B, Sullitlo A, Cierwo A, Inlano N, Rinaldi L, Santoro A, Li Vigni G, Marrone A. Chronic HCV infection is a risk factor of ischemic stroke. Atherosclerosis 2013; 231: 22-26 [PMID: 24125405 DOI: 10.1016/j.atherosclerosis.2013.08.003]

Hsu CS, Kao JH, Chao YC, Lin HH, Fan YC, Huang CJ, Tsai PS. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Aliment Pharmacol Ther 2013; 38: 415-423 [PMID: 23802888 DOI: 10.1111/1365-2036.12391]

Karibe H, Niiizuma H, Ohyama H, Shirane R, Yoshimoto T. Hepatitis C virus (HCV) infection as a risk factor for spontaneous intracerebral hemorrhage: hospital based case-control study. J Clin Neurosci 2001; 8: 423-425 [PMID: 11535009 DOI: 10.1016/j.jocn.2001.08.011]

Tseng CH, Muo CH, Hsu CY, Kao CH. Increased Risk of Intracerebral Hemorrhage Among Patients With Hepatitis C Virus Infection. Medicine (Baltimore) 2015; 94: e2132 [PMID: 26579831 DOI: 10.1097/MD.000000000001233]

Hsu YH, Muo CH, Liu CY, Tsai WC, Hsu CC, Sung FC, Kao CH. Hepatitis C virus infection increases the risk of developing peripheral arterial disease: a 9-year population-based cohort study. J Hepatol 2015; 62: 519-525 [PMID: 25263004 DOI: 10.1016/j.jhep.2014.09.022]

Guiltinan AM, Kaidarova Z, Custer B, Orland J, Strollo A, Cyrus with HIV vs. HIV seroconversion at older age: a diverse population cohort study. J Infect Dis 2013; 265: 218-224 [PMID: 23784666 DOI: 10.1093/infdis/jits572]

Lee MH, Yang HI, Wang JC, Chen CJ, Aldrovandi C, Nardini G, Beghetto B, Borghi V, Bertolotti C, Grazia Amorico M, Roverato A, Esposito R. Multidisciplinary approach to the treatment of metabolic and cardio-cerebrovascular disease. Metabolic alterations and chronic hepatitis C: treatment strategies. Expert Opin Pharmacother 2011; 12: 2215-2234 [PMID: 21883025 DOI: 10.1517/14656566.2011.977420]

Jepson P, Watson H, Andersen PK, Vilstrup H. Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients. J Hepatol 2015; 63: 1133-1138 [PMID: 26206073 DOI: 10.1016/j.jhep.2015.07.007]

El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology 2016; 64: 130-137 [PMID: 26946190 DOI: 10.1002/hep.20855]

Singal AG, El-Serag HB. Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clin Gastroenterol Hepatol 2015; 13: 2140-2151 [PMID: 26284591 DOI: 10.1016/j.cgh.2015.08.014]

Thompson AJ, Patel K, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Rustgi VK, Fliksi R, Pianko S, Diago M, Arora S, Foster GR, Torbenson M, Benhamou Y, Nelson DR, Sulkowski MS, Zuzenm S, Pulkstenis E, Subramanian GM, McHutchison JG. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut 2012; 61: 128-134 [PMID: 21873466 DOI: 10.1136/gut.2010.236158]

Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364 [PMID: 11391523 DOI: 10.1053/jhep.2001.24432]

Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zuzenm S, Vouinos Z, Albrecht J. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 37: 75-85 [PMID: 12829989 DOI: 10.1053/jhep.2003.50267]

Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G. Hepatitis C and steatosis: a reappraisal. J Viral Hepat 2006; 13: 73-80 [PMID: 16436124 DOI: 11.1111/j.1365-2893.2005.00669.x]

Global-AIDS-update-2016_en.pdf [Internet]. unaids.org [cited 2016-06-30]. Available from: URL: http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf

Sabin CA. Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy? BMC Med 2013; 11: 251 [PMID: 24283830 DOI: 10.1186/1741-7015-11-251]

Greene M, Justice AC, Lampiris HW, Valcour V. Management of human immunodeficiency virus infection in advanced age. JAMA 2013; 309: 1397-1405 [PMID: 23549585 DOI: 10.1001/jama.2013.2963]

De Cock KM, El-Sadr WM, Ghebreyesus TA. Game changers: why did the scale-up of HIV treatment work despite weak health systems? J Acquir Immune Defic Syndr 2011; 57 Suppl 2: S61-S63 [PMID: 21857297 DOI: 10.1097/QAI.0b013e3182217f00]

Rodger AJ, Lodwick R, Schechter M, Deeks S, Amin J, Gilson R, Paredes R, Bakowska E, Engsig FN, Phillips A. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013; 27: 973-979 [PMID: 23690863 DOI: 10.1097/QAD.0b013e32835ae9e4]

Cooperman NA, Arnsten JH, Klein RS. Current sexual activity and risky sexual behavior in older men with or at risk for HIV infection. AIDS Educ Prev 2007; 19: 321-333 [PMID: 17685845 DOI: 10.1521/aeap.2007.19.4.321]

Guaraldi G, Zona S, Brothers TD, Carli F, Stentarelli C, Dolci G, Santoro A, Beghetto M, Fenozzi M, Massini C, Falatu J. Aging with HIV vs. HIV serocconversion at older age: a diverse population with different comorbidity profiles. PLoS One 2015; 10: e0118351 [PMID: 25874806 DOI: 10.1371/journal.pone.0118531]

Guaraldi G, Orlando G, Squillace N, De Santis G, Pedone A, Spaggiari A, De Fazio D, Vandelli M, De Paola M, Bertuccelli C, Aldrovandi C, Nardini G, Beghetto B, Borghi V, Bertolotti M, Bagini B, Grazia Amorico M, Roverato A, Esposito R. Multidisciplinary approach to the treatment of metabolic and cardiovascular disease.
Fatty liver increases the risk of type 2 diabetes and cardiovascular disease

morphologic alterations of HIV-related lipodystrophy. JAMA Intern Med 2013; 173: 614-622 [PMID: 23459865 DOI: 10.1001/jamainternmed.2013.3728]

233 Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-2512 [PMID: 17456578 DOI: 10.1210/jc.2006-2190]

234 Marin B, Thiébaut R, Buccher HC, Rondoue V, Costagliola D, Dorrucci M, Hamouda O, Prins M, Walker S, Porter K, Sabin C, Chêne G. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009; 23: 1743-1753 [PMID: 19571723 DOI: 10.1097/QAD.0b013e328362e87f]

235 Baker JV, Peng G, Rapkin J, Abrams DI, Silverberg MJ, MacArthur RD, Cavert WP, Henry WK, Neaton JD. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22: 841-848 [PMID: 18427202 DOI: 10.1097/QAD.0b013e32827cb76f]

236 Debasieux S, Rayne F, Yezid H, Beaumelle B. The ins and outs of HIV-1 Tat. Traffic 2012; 13: 355-363 [PMID: 21955152 DOI: 10.1111/j.1600-0854.2011.01286.x]

237 Dhawan S, Puri RK, Kumar A, Duplan H, Masson JM, Aggarwal BB. Human immunodeficiency virus-tat protein induces the cell surface expression of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in human endothelial cells. Blood 1997; 90: 1535-1544 [PMID: 9269771]

238 Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM, Boerwinkle E. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997; 96: 4219-4225 [PMID: 9416885]

239 Puppo F, Brensi S, Scudeletti M, Lanza L, Bosco O, Indiveri F. Elevated serum levels of circulating intercellular adhesion molecule-1 in HIV infection. AIDS 1993; 7: 593-594 [PMID: 8099491]

240 Paladugu R, Fu W, Conklin BS, Lin PH, Lumsden AB, Yao Q, Chen C. HIV Tat protein causes endothelial dysfunction in porcine coronary arteries. J Vasc Surg 2003; 38: 549-555; discussion 555-556 [PMID: 12947275]

241 Shikuma CM, Barbour JD, Ndhlovu LC, Keating SM, Norris PJ, Budoff M, Parikh N, Seto T, Ganguero LM, Ogata-Arakaki D, Chow D. Plasma monocyte chemoattractant protein-1 and tumor necrosis factor-α levels predict the presence of coronary artery calcium in HIV-infected individuals independent of traditional cardiovascular risk factors. AIDS Patient Care STDS 2011; 25(1): 42-43 [PMID: 21939060 DOI: 10.1089/QAD.0b013e3282f7cb76]

242 Herder C, Brummer RJ, Rathmann W, Strassburger K, Tabák AG, Schloot NC, Witte DR. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care 2009; 32: 421-423 [PMID: 19073760 DOI: 10.2337/dc08-1161]
Lonardo A et al. Fatty liver increases the risk of type 2 diabetes and cardiovascular disease

DOI: 10.1086/313854

248 Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors. *Hepatology* 2010; 52: 71-78 [PMID: 20578130 DOI: 10.1002/hep.23619]

249 Guaraldi G, Squillace N, Stentarelli C, Orlando G, D’Amico R, Ligabue G, Fiocchi F, Zona S, Loria P, Esposito R,Palella F. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. *Clin Infect Dis* 2008; 47: 250-257 [PMID: 18532884 DOI: 10.1086/589294]

250 Crum-Cianflone N, Dilay A, Collins G, Asher D, Campin R, Medina S, Goodman Z, Parker R, Liñon A, Capozza T, Bavaro M, Hale B, Hames C. Nonalcoholic fatty liver disease among HIV-infected persons. *J Acquir Immune Defic Syndr* 2009; 50: 464-473 [PMID: 19225402 DOI: 10.1097/QAI.0b013e318198a88a]

251 Castéra L, Loko MA, Le Bail B, Coffie P, De Ledinghen V, Trimoulet P, Winnock M, Dabis F, Neau G, Neu A. Hepatic steatosis in HIV-HCV coinfected patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype. *Aliment Pharmacol Ther* 2007; 26: 1489-1498 [PMID: 17903235 DOI: 10.1111/j.1365-2036.2007.03533.x]

252 Woreta TA, Sutcliffe CG, Mehta SH, Brown TT, Higgins Y, Thomas DL, Torbenson MS, Moore RD, Sulkowski MS. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. *Gastroenterology* 2011; 140: 809-817 [PMID: 21134375 DOI: 10.1053/j.gastro.2010.11.052]

253 McGovern BH. Hepatic steatosis in HIV/HCV-coinfected patients: time to reevaluate! *Gastroenterology* 2011; 140: 772-775 [PMID: 21276645 DOI: 10.1053/j.gastro.2011.01.025]

254 Vodkin I, Valasek MA, Bettencourt R, Cachay E, Loomba R. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study. *Aliment Pharmacol Ther* 2015; 41: 368-378 [PMID: 25496369 DOI: 10.1111//apt.13052]

255 Brown TT, Glesby MJ. Management of the metabolic effects of HIV and HIV drugs. *Nat Rev Endocrinol* 2011; 8: 11-21 [PMID: 21931374 DOI: 10.1038/rendo.2011.151]

256 Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somoro M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor in patients with HIV. *N Engl J Med* 2007; 357: 2359-2370 [PMID: 18057338 DOI: 10.1056/NEJMoa072375]

257 Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. *JAMA* 2014; 312: 380-389 [PMID: 25038357 DOI: 10.1001/jama.2014.8334]

258 Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahaepatic disease. *Gastroenterology* 2004; 126: 586-597 [PMID: 14762795]

259 Byrne CD, Tarberger N. NAFLD: a multisystem disease. *J Hepatol* 2015; 62: S47-S64 [PMID: 25920090 DOI: 10.1016/j.jhep.2014.12.012]

260 Nascimbeni F, Puis R, Bellentani S, Day CP, Ratziu V, Loria P, Lonardo A. From NAFLD in clinical practice to answers from guidelines. *J Hepatol* 2013; 59: 859-871 [PMID: 23751754 DOI: 10.1016/j.jhep.2013.05.044]

261 European Association for the Study of the Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol* 2016; 64: 1388-1402 [PMID: 27062661 DOI: 10.1016/j.jhep.2015.11.004]

262 Nix LM, Tien PC. Metabolic syndrome, diabetes, and cardiovascular risk in HIV. *Curr HIV/AIDS Rep* 2014; 11: 271-278 [PMID: 25027062 DOI: 10.1007/s11904-014-0219-7]

263 Hemkens LG, Bucher HC. HIV infection and cardiovascular disease. *Eur Heart J* 2014; 35: 1373-1381 [PMID: 24408888 DOI: 10.1093/eurheartj/ehu258]

264 Vallet-Pichard A, Mallet V, Pol S. Nonalcoholic fatty liver disease and HIV infection. *Semin Liver Dis* 2012; 32: 158-166 [PMID: 22760655 DOI: 10.1055/s-0032-1316471]
